Once-Daily GLP-1 Agonist, Lixisenatide, Licensed in EUOnce-Daily GLP-1 Agonist, Lixisenatide, Licensed in EU

Another GLP-1 agonist is entering the type 2 diabetes market, in the form of once-daily lixisenatide, which has been approved in the EU. It will compete with liraglutide and exenatide. International Approvals

Source: Medscape Today Headlines - February 4, 2013 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news